Abstract
We show that an individual’s immune status to Covid-19 can be monitored through quantitative antibody measurements using a method specifically designed for high throughput and accuracy from a finger-prick blood sample. The quality of the rapid test results is comparable to that from major commercial laboratory testing kits. Anti-Receptor Binding Domain (RBD) IgG concentration showed a log-normal distribution with mean decreasing with time following the second vaccination with mRNA BNT162b2 (Pfizer). Using a model for an individual’s antibody concentration-dependent vaccine efficacy allowed comparison with literature data on changing vaccine efficacy against symptomatic disease across a population. In this small trial (n = 100) estimated median vaccine efficacy was 90% (range 65-95%) < 90 days post vaccination, 75% (range 35 – 90%) 90 – 170 days and 65% (range 35-90%) 170 – 230 days. The results provide strong support for personalized booster programmes that, by targeting people in the tail of the distribution, should be more effective at diminishing breakthrough infection and optimising booster dose supply than a program that simply mandates a booster at a specific post-vaccination time point.
Competing Interest Statement
MCS and KCJ are Directors of Orbis Diagnostic Ltd. Other than AT, authors are shareholders and/or employees of Orbis Diagnostics Ltd or its lead investor, Pacific Channel.
Clinical Trial
ACTRN12621000907842 U1111-1267-3749
Clinical Protocols
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382309&isReview=true
Funding Statement
This study was funded by Orbis Diagnostics Ltd
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Trail registered on Australia New Zealand Clinical Trials Registry. Registration number ACTRN12621000907842; Universal Trial Number U1111-1267-3749 Ethics approval to Orbis Diagnostics Ltd by Health and Disability Ethics Committees, 133 Molesworth Street, Thorndon, Wellington, 6011, New Zealand Approval number 21/NTB/212
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript or supplementary appendices
